Versant Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.8K Hold
266
– – ﹤0.01% 2170
2026
Q2
$10.4K Buy
266
+29
+12% +$894 ﹤0.01% 2217
2026
Q1
$6.41K Buy
237
+13
+6% +$437 ﹤0.01% 2316
2025
Q4
$9.6K Hold
224
– – ﹤0.01% 2016
2025
Q3
$6.35K Sell
224
-1
-0.4% -$30 ﹤0.01% 2113
2025
Q2
$4.21K Buy
225
+93
+70% +$1.76K ﹤0.01% 2214
2025
Q1
$2.38K Buy
132
+9
+7% +$183 ﹤0.01% 2247
2024
Q4
$2.07K Buy
+123
New +$2.36K ﹤0.01% 2054

Other funds holding RIGL

Versant Capital Management's RIGL Position: Q3 2026 in Review

Versant Capital Management held its Rigel Pharmaceuticals (RIGL) position steady in Q3 2026 at 266 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

Versant Capital Management first reported a position in RIGL in Q4 2024 and has held it in 8 quarters since. 151 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

  • Versant Capital Management held 266 shares of Rigel Pharmaceuticals worth $12.8K as of Q3 2026.
  • Versant Capital Management left its Rigel Pharmaceuticals share count unchanged in Q3 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2170 holding.
  • Versant Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • 151 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.